

Building for future growth from a position of strength

Expand manufacturing capacity

Ensuring growth with and beyond semaglutide LoE

Expand and progress pipeline within core therapy areas

Manufacturing scale and expertise is a competitive advantage for Novo Nordisk

Continue driving growth in diabetes care with semaglutide, supported by outcomes trials

Clear strategy and portfolio priorities

Continued CAPEX investments and scaling across supply chain

Continue building the obesity market

Expand pipeline by strengthening and applying core capabilities, technology platforms and business development

Plans in place to enable a significant increase of patient reach towards 2030

Back to sustained growth in Rare disease

Successfully develop late-stage clinical pipeline

Reaching more patients and being a sustainable business

